~ Newly Discovered Benefits of Aspirin - References

References

1. Crofford LJ. Prostaglandin biology. Gastroenterol Clin North Am. 2001 Dec;30(4):863-76.

2. Available at: http://en.wikipedia.org/wiki/Thromboxane. Accessed May 8, 2006.

3. Bayer A. Clinicians’ Guide to Aspirin. London: Arnold; 1998.

4. Norman AW, Litwack G. Hormones. 2nd ed. Burlington, MA: Academic Press; 1997.

5. Available at: http://en.wikipedia.org/wiki/ Aspirin. Accessed May 8, 2006.

6. McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging. 2005 Dec;26 Suppl 1:94-7.

7. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006 Feb;83(2):447S-55S.

8. Roberts LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, eds. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001: 687-731.

9. Available at: http://www.answers.com/ nsaids. Accessed May 9, 2006.

10. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006 Feb;6(2):130-40.

11. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17.

12. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006 Jan;55(1):115-22.

13. Bruce DF. Nutritional strategies for conquering colon cancer. Life Extension. March, 2005:48-56.

14. Available at: http://www.abc.net.au/worldtoday/content/2005/s1499391.htm. Accessed April 27, 2006.

15. Available at: http://www.emaxhealth.com/ 101/3662.html. Accessed April 27, 2006.

16. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005 Dec 12;5:159.

17. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006 Jan;17(1):104-7.

18. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003 Mar 6;348(10):891-9.

19. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 6;348(10):883-90.

20. van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, van der Flier WM. Hippocampal atrophy in Alzheimer disease: age matters. Neurology. 2006 Jan 24;66(2):236-8.

21. Available at: http://www.nia.nih.gov/ Alzheimers/ResearchInformation/NewsReleases/Archives/PR1997/PR19970310NSAID.htm. Accessed April 27, 2006.

22. Ho L, Pieroni C, Winger D, et al. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease. J Neurosci Res. 1999 Aug 1;57(3):295-303.

23. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc. 2003 May;51(5 Suppl Dementia):S296-S304.

24. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002 Sep 24;59(6):880-6.

25. in ‘t, V, Launer LJ, Breteler MM, Hofman A, Stricker BH. Pharmacologic agents associated with a preventive effect on Alzheimer’s disease: a review of the epidemiologic evidence. Epidemiol Rev. 2002;24(2):248-68.

26. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003 Jul 19;327(7407):128.

27. Nilsson SE, Johansson B, Takkinen S, et al. Does aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol. 2003 Aug;59(4):313-9.

28. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998 Mar 3;97(8):716-20.

29. Available at: http://www.cnn.com/HEALTH/ library/DS/00691.html. Accessed May 8, 2006.

30. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of athero-thrombosis. Am J Cardiovasc Drugs. 2005;5(6):399-408.

31. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-43.

32. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 Sep 22;163(17):2006-10.

33. Available at: http://foxnews.webmd.com/ content/article/115/111752.htm. Accessed April 27, 2006.

34. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006 Jan 18;295(3):306-13.

35. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002 Jan 15;136(2):161-72.

36. Available at: http://www.americanheart.org/ presenter.jhtml?identifier=4704. Accessed April 26, 2006.

37. Savon JJ, Allen ML, DiMarino AJ Jr, Hermann GA, Krum RP. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol. 1995 Apr;90(4):581-5.

38. Bowman J. Strokes. Upper Saddle River, NJ: Prentice Hall; 2003.

39. Anon. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002 Jan 15;136(2):157-60.

40. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352(13):1293-304.

41. Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol. 2005;(170):107-33.

42. Dempster DW, Rosenstock JL, Scwimmer JA, Panagopoulos G, DeVita MV, Michelis MF. Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease. Clin Nephrol. 2005 Nov;64(5):371-7.

43. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006 Feb 1;295(5):547-53.

44. Kelemen MD. Angina pectoris: evaluation in the office. Med Clin North Am. 2006 May;90(3):391-416.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.